Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2024-12-13 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
东莞证券股份有限公司关于特一药业集团股份有限公司持续督导现场培训报告
Board/Management Information Classification · 95% confidence The document is titled as a "持续督导现场培训报告" (Continuous Supervision On-site Training Report) by Dongguan Securities for Te Yi Pharmaceutical Group Co., Ltd. It describes a training session conducted on December 2, 2024, for the company's controlling persons, directors, supervisors, senior management, securities affairs representatives, and finance managers. The content focuses on regulatory updates such as new rules on share reduction, market value management guidelines, and merger and acquisition policies. The document is a report on the training activity itself, not a financial report, regulatory filing, or announcement of voting results. It is a specialized report related to board/management information and compliance training for senior management and directors. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short (1162 characters), and it is not an announcement of a report publication or a certification letter, so RPA or RNS are not suitable.
2024-12-13 Chinese
关于2021年股票期权激励计划第三个行权期采用自主行权模式的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the 2021 stock option incentive plan's third exercise period for a company named 特一药业集团股份有限公司. It includes extensive information about the stock option plan, exercise conditions, adjustments to the number and price of stock options, cancellations, and the impact on the company's share structure and financials. The document also references board meetings and approvals related to the stock option plan. The content is focused on stock option incentive plan details, exercise conditions, and related corporate governance matters. This type of document is typically classified as a Capital/Financing Update (CAP) because it deals with stock option plans, share issuance related to employee incentives, and capital structure changes. It is not an annual report, earnings release, or management report, nor is it a simple announcement of voting results or a regulatory filing. The document length and detail confirm it is not a brief announcement but a substantive update on capital-related matters.
2024-12-11 Chinese
关于2021年股票期权激励计划部分股票期权注销完成的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of the cancellation of certain stock options under the company's 2021 stock option incentive plan. It details the procedural history, reasons for cancellation, and the impact on the company. There are no financial statements or comprehensive financial data presented. The document is a formal announcement about stock option cancellations, which relates to changes in capital structure but is not a full capital change announcement like a new share issue or stock split. It is not a report or presentation but a regulatory announcement about stock option cancellations. Given the content and nature, the best fitting category is Regulatory Filings (RNS), as it is a formal disclosure that does not fit other more specific categories such as Capital/Financing Update or Share Issue/Capital Change, since it is about stock option cancellations and related procedural disclosures.
2024-12-09 Chinese
关于注销2021年股票期权激励计划部分股票期权的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the cancellation of part of its 2021 stock option incentive plan. It details board and supervisory meetings, legal opinions, and specific stock option adjustments and cancellations. The content focuses on corporate governance actions related to stock options, including approvals and procedural compliance. It does not contain financial statements, earnings data, or detailed financial analysis. It is not a full annual or interim report, nor is it a call transcript or earnings release. It is not a proxy solicitation or voting results announcement. The document is a regulatory announcement about changes in stock option incentives, which fits best under Regulatory Filings (RNS) as it is a formal disclosure of corporate actions and compliance with regulations but does not fit other more specific categories like Remuneration Information or Share Issue/Capital Change since it is about stock option cancellations rather than new share issues or executive compensation details. The document length is about 5,000 characters, and it is a full announcement, not just a report publication notice. Therefore, the best classification is Regulatory Filings (RNS).
2024-12-02 Chinese
关于第五届监事会第二十四次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at the 24th meeting of the 5th Supervisory Board of 特一药业集团股份有限公司. It includes details on stock option cancellations, approval of stock option exercise conditions, reappointment of the audit firm, changes to registered capital and company bylaws, and changes in the use of raised funds. The document is a formal meeting resolution announcement by the supervisory board, not a full financial report or audit report. It does not contain financial statements or detailed financial analysis. It is also not a proxy solicitation or voting result announcement but a meeting resolution announcement. Given the content and nature, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-12-02 Chinese
关于股份回购进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement by 特一药业集团股份有限公司 regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total funds used, and compliance with relevant regulations. The document is relatively short (1426 characters) and focuses on the update of the share buyback activity rather than presenting financial statements or comprehensive financial data. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2024-12-02 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.